Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 13/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13075228 | 0.88 | PRKCQ (0.51) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL10310903 | 0.87 | PRKCQ (0.58) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL292279 | 0.81 | PRKCQ (0.68) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL10277118 | 0.80 | PRKCQ (0.55) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL3798633 | 0.80 | PRKCQ (0.59) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL10310900 | 0.78 | PRKCQ (0.53) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL10310901 | 0.74 | PRKCQ (0.41) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL2675503 | 0.71 | PRKCQ (1.00) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL10276910 | 0.71 | PRKCQ (0.46) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917723 | 0.71 | PRKCQ (0.80) | PRKCQJAK2ROCK2PRKCDROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2010129668-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178778-A1 | PYRAZOLOPYRIDINES | MAP3K5, MAP4K5, MAP3K20 | PRKCQ 41/4885JAK2 230/4885ROCK2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.